What is the main topic?

The main topic is the EMA's approval for Novo Nordisk to update Ozempic's label to include kidney disease risk reduction.

What did the trial demonstrate?

The trial demonstrated that semaglutide reduces the risk of kidney disease progression.

When is the US decision expected?

Novo Nordisk expects to hear back from the US regarding the label update in the first half of 2025.

Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Finance > Europe allows Novo to include reduction of kidney disease in Ozempic label

Finance

Europe allows Novo to include reduction of kidney disease in Ozempic label

Published by Global Banking & Finance Review®

Posted on December 12, 2024

1 min read

Last updated: January 27, 2026

Private equity market challenges in Europe amid changing financial landscape - Global Banking & Finance Review — This image illustrates the complexities faced by private equity firms in Europe as they navigate exit challenges and seek lucrative deals, reflecting the current financial climate discussed in the article.

Europe allows Novo to include reduction of kidney disease in Ozempic label

Quick Summary

EMA Approves Ozempic Label Update for Kidney Disease Reduction

Key Takeaways

Frequently Asked Questions about Europe allows Novo to include reduction of kidney disease in Ozempic label